Table 1.

SMO inhibitors used in clinical trials.

SMO Inhibitors	National Clinical Trial (NCT)	Tumor Type
Vismodegib (GDC-0449)	e.g., NCT03035188, NCT02115828	BCC, prostate cancer
Sonidegib (NVP-LDE225)	e.g., NCT02111187, NCT04066504,	Prostate cancer, BCC,
Glasdegib (PF-04449913)	e.g., NCT03466450, NCT04231851	Glioblastoma, AML
Saridegib (IPI-926)	e.g., NCT01609179	BCC
Taladegib (LY-2940680)	e.g., NCT01226485	Advanced cancer
TAK-441	e.g., NCT01204073	Advanced nonhematologic malignancies
BMS-833923 (XL139)	e.g., NCT01413906, NCT00670189	Solid tumors, BCC
Itraconazole	e.g., NCT01791894	BCC